BioSpace News Archive

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has decided not to adopt the CHMP’s negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation.

mBIOTA Labs today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two.

Intercept Pharmaceuticals, Inc. is presenting two new sub-analyses from its Phase 3 POISE study in primary biliary cholangitis (PBC), at Digestive Disease Week® (DDW) 2024 in Washington, D.C.

Volta Medical announced positive results from the transatlantic, multicenter, randomized, controlled, superiority trial titled Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation (TAILORED-AF) at Heart Rhythm 2024 Late Breaking Clinical Trials and Science program.

Scorpius Holdings, Inc, an integrated contract development and manufacturing organization, announced a significant expansion of its operational footprint in San Antonio, Texas, with the opening of its new, state-of-the-art storage and testing facility.

Duoning Biotechnology Group (“Duoning”), a leading one-stop bioprocess provider in China, today announced a strategic partnership with Bioelectronica, a company focusing on developing tools for single-cell/single-bacteria research.

Ensysce Biosciences, Inc. today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.

Approximately 10% of people diagnosed with cancer experience hypersensitivity reactions to certain therapies—which range from a mild skin rash to anaphylaxis —even when they were pretreated with antihistamines and steroids.

LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s recent activities, including notable pre-clinical developments.

The National Comprehensive Cancer Network® announced publication of new NCCN Guidelines for Patients®: Small Bowel Adenocarcinoma.